Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT01210222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NETWORK

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Endometrial Serous Adenocarcinoma
Endometrioid Stromal Sarcoma
Recurrent Uterine Corpus Carcinoma

Interventions

BIOLOGICAL: Trebananib

Sponsor

Gynecologic Oncology Group

Collaborators

[object Object]